<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELMIRON- pentosan polysulfate sodium capsule, gelatin coated </strong><br>Cardinal Health<br></p></div>
<h1>ELMIRON<span class="Sup">®</span>-100 mg <br>(pentosan polysulfate sodium) <br>Capsules </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92295379-5f9e-4641-8082-fc08d6d3968f"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">PRESCRIBING INFORMATION</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_920fbf04-dfe7-49a9-bb78-b185f9e10c48"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6. It has a molecular weight of 4000 to 6000 Dalton with the following structural formula:</p>
<div class="Figure">
<a name="id258"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b172ad2-074f-4534-af1f-89d951647ee9&amp;name=image-01.jpg">
</div>
<p>ELMIRON<span class="Sup">®</span> is supplied in white opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate. It also contains pharmaceutical glaze (modified) in SD-45, synthetic black iron oxide, FD&amp;C Blue No. 2 aluminum lake, FD&amp;C Red No. 40 aluminum lake, FD&amp;C Blue No. 1 aluminum lake, D&amp;C Yellow No. 10 aluminum lake, n-butyl alcohol, propylene glycol, SDA-3A alcohol, and titanium dioxide. It is formulated for oral use.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_28d0b4c7-671d-4581-b941-1deb90551e12"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9059c0f7-aaa7-4c24-9548-e942bc7998f5"></a><a name="section-3.1"></a><p></p>
<h2>General</h2>
<p class="First">Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. The mechanism of action of pentosan polysulfate sodium in interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> is not known.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9e1cdc55-b9b8-4835-8a8b-222bd2f91c26"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b03eb544-acae-4039-b456-29cbe7d59c9a"></a><a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6-120 hours) after dosing. Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69b3880d-3929-4548-9e68-83a7498abd91"></a><a name="section-3.2.1.1"></a><p></p>
<h4>Food Effects</h4>
<p class="First">In clinical trials, ELMIRON<span class="Sup">®</span> was administered with water 1 hour before or 2 hours after meals; the effect of food on absorption of pentosan polysulfate sodium is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c667cd5a-b6a2-485f-9cb4-d5726d2bcb6c"></a><a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Preclinical studies with parenterally administered radiolabeled pentosan polysulfate sodium showed distribution to the uroepithelium of the genitourinary tract with lesser amounts found in the liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low in animals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77a3162b-9f9f-485c-834a-c5003c7bd7de"></a><a name="section-3.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">The fraction of pentosan polysulfate sodium that is absorbed is metabolized by partial desulfation in the liver and spleen, and by partial depolymerization in the kidney to a large number of metabolites. Both the desulfation and depolymerization can be saturated with continued dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_795b76f5-0c19-43cf-8b5d-5cce6c8dc566"></a><a name="section-3.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Following administration of an oral solution of a 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug to groups of healthy subjects, plasma radioactivity declined with mean half-lives of 27 and 20 hours, respectively. A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug. A mean of 6% of an oral dose is excreted in the urine, mostly as desulfated and depolymerized metabolites. Only a small fraction of the administered dose (mean 0.14%) is recovered as intact drug in urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de07e8bf-648d-4069-99a3-448f2e571c11"></a><a name="section-3.2.5"></a><p></p>
<h3>Special Populations</h3>
<p class="First">The pharmacokinetics of pentosan polysulfate sodium has not been studied in geriatric patients or in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. See also <span class="Italics"><a href="#i4i_section_id_9a8cfc32-f9e6-49b1-8df9-596946fc4f34">PRECAUTIONS-<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_885503e4-df2c-4e16-ba38-a8240277cb11"></a><a name="section-3.2.6"></a><p></p>
<h3>Drug-Drug Interactions</h3>
<p class="First">In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium. INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also <span class="Italics"><a href="#i4i_precautions_id_04abcadb-c70c-4f88-ba54-551ddeee3b6f">PRECAUTIONS</a></span> on the use of ELMIRON<span class="Sup">®</span> in patients receiving other therapies with anticoagulant effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c0d1b8f1-4320-4721-9520-53595290e3e3"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The mechanism by which pentosan polysulfate sodium achieves its effects in patients is unknown. In preliminary clinical models, pentosan polysulfate sodium adhered to the bladder wall mucosal membrane. The drug may act as a buffer to control cell permeability preventing irritating solutes in the urine from reaching the cells.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_82c4657e-053e-428b-ba89-d3513ef8127b"></a><a name="section-4"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">ELMIRON<span class="Sup">®</span> was evaluated in two clinical trials for the relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients with chronic interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> (IC). All patients met the NIH definition of IC based upon the results of cystoscopy, <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and biopsy. One blinded, randomized, placebo-controlled study evaluated 151 patients (145 women, 5 men, 1 unknown) with a mean age of 44 years (range 18 to 81). Approximately equal numbers of patients received either placebo or ELMIRON<span class="Sup">®</span> 100 mg three times a day for 3 months. Clinical improvement in <span class="product-label-link" type="condition" conceptid="4048710" conceptname="Bladder pain">bladder pain</span> was based upon the patient's own assessment. In this study, 28/74 (38%) of patients who received ELMIRON<span class="Sup">®</span> and 13/74 (18%) of patients who received placebo showed greater than 50% improvement in <span class="product-label-link" type="condition" conceptid="4048710" conceptname="Bladder pain">bladder pain</span> (p = 0.005).</p>
<p>A second clinical trial, the physician's usage study, was a prospectively designed retrospective analysis of 2499 patients who received ELMIRON<span class="Sup">®</span> 300 mg a day without blinding. Of the 2499 patients, 2220 were women, 254 were men, and 25 were of unknown sex. The patients had a mean age of 47 years and 23% were over 60 years of age. By 3 months, 1307 (52%) of the patients had dropped out or were ineligible for analysis, overall, 1192 (48%) received ELMIRON<span class="Sup">®</span> for 3 months; 892 (36%) received ELMIRON<span class="Sup">®</span> for 6 months; and 598 (24%) received ELMIRON<span class="Sup">®</span> for one year.</p>
<p>Patients had unblinded evaluations every 3 months for the patient's rating of overall change in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in comparison to baseline and for the difference calculated in "<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>" scores. At baseline, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> scores for the original 2499 patients were severe or unbearable in 60%, moderate in 33% and mild or none in 7% of patients. The extent of the patients' <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> improvement is shown in <a href="#_RefIDE0ACD6E7B43242D8B97EB8F5143F424A">Table 1</a>.</p>
<p>At 3 months, 722/2499 (29%) of the patients originally in the study had <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores that improved by one or two categories. By 6 months, in the 892 patients who continued taking ELMIRON<span class="Sup">®</span>, an additional 116/2499 (5%) of patients had improved <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores. After 6 months, the percent of patients who reported the first onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief was less than 1.5% of patients who originally entered in the study (see <a href="#_RefID07DB34E304E347619830F002226F689D">Table 2</a>).</p>
<a name="_RefIDE0ACD6E7B43242D8B97EB8F5143F424A"></a><table width="100%">
<caption><span>Table 1: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Scores in Reference to Baseline in Open Label Physician's Usage Study (N = 2499)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="18%">
<col width="10%">
<col width="10%">
<thead><tr class="First Last Toprule">
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule" align="center" valign="top">
<span class="Bold">3 months</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">6 months</span><a href="#footnote-2" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Trial not designed to detect onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>CI = 95% confidence interval</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>6-point scale: 1 = worse, 2 = no better, 3 = slightly improved, 4 = moderately improved, 5 = greatly improved, 6 = symptom gone</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>3-point scale: 1 = none or mild, 2 = moderate, 3 = severe or unbearable</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule"><p class="First">Patient Rating of Overall Change in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (Recollection of difference between current <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Lrule"><p class="First">N = 1161<br>Median = 3<br>Mean = 3.44<br>CI: (3.37, 3.51)</p></td>
<td class="Lrule Rrule"><p class="First">N = 724<br>Median = 4<br>Mean = 3.91<br>CI: (3.83, 3.99)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> </p></td>
<td class="Lrule"><p class="First"> </p></td>
<td class="Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule"><p class="First">Change in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span> Score (Calculated difference in scores at the time point and baseline)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></p></td>
<td class="Lrule"><p class="First">N = 1440<br>Median = 1<br>Mean = 0.51<br>CI: (0.45, 0.57)</p></td>
<td class="Lrule Rrule"><p class="First">N = 904<br>Median = 1<br>Mean = 0.66<br>CI: (0.61, 0.71)</p></td>
</tr>
</tbody>
</table>
<a name="_RefID07DB34E304E347619830F002226F689D"></a><table width="100%">
<caption><span>Table 2: Number (%) of Patients with New Relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> in the Open-Label Physician's Usage Study (N = 2499) </span></caption>
<col width="14%">
<col width="11%">
<col width="11%">
<thead><tr class="First Last Toprule">
<th class="Botrule Lrule" align="left" valign="top"></th>
<th class="Botrule Lrule" align="center" valign="top">
<span class="Bold">at 3 months</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a><br><span class="Bold">(n = 1192)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">at 6 months</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a><br><span class="Bold">(n = 892)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>First-time Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> score by 1 or 2 categories</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Number (%) of patients with improvement of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> score at 3 months when compared to baseline</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Number (%) of patients without <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> improvement at 3 months who had improvement at 6 months</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule"><p class="First">Considering only the patients who continued treatment</p></td>
<td class="Lrule"><p class="First">722/1192 (61%)</p></td>
<td class="Lrule Rrule"><p class="First">116/892 (13%)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> </p></td>
<td class="Lrule"><p class="First"> </p></td>
<td class="Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule"><p class="First">Considering all the patients originally enrolled in the study</p></td>
<td class="Lrule"><p class="First">722/2499 (29%)</p></td>
<td class="Lrule Rrule"><p class="First">116/2499 (5%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b1afeb26-7fb2-4a54-9269-ade6281ddaa6"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ELMIRON<span class="Sup">®</span> (pentosan polysulfate sodium) is indicated for the relief of <span class="product-label-link" type="condition" conceptid="4048710" conceptname="Bladder pain">bladder pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4d771c1d-b9e1-4659-a4a0-13e2a1aa462f"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ELMIRON<span class="Sup">®</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug, structurally related compounds, or excipients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bb72384a-37c3-4d3b-9cc0-3146b31e1a5f"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_04abcadb-c70c-4f88-ba54-551ddeee3b6f"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_5ba384e2-7eeb-4aa3-8450-2ac24b0aefc1"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">ELMIRON<span class="Sup">®</span> is a weak anticoagulant (1/15 the activity of heparin). At a daily dose of 300 mg (n = 128), <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> was reported as an adverse event in 6.3% of patients. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications of <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span> have been reported (see <span class="Bold"><span class="Italics"><a href="#i4i_adverse_effects_id_00be3d73-5779-45da-8a80-761918eeae8b">ADVERSE REACTIONS</a></span></span>). Patients undergoing invasive procedures or having signs/symptoms of underlying <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> or other increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (due to other therapies such as coumarin anticoagulants, heparin, t-PA, streptokinase, high dose aspirin, or nonsteroidal anti-inflammatory drugs) should be evaluated for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Patients with diseases such as <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysms</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>, gastrointestinal ulcerations, <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>, or diverticula should be carefully evaluated before starting ELMIRON<span class="Sup">®</span>.</p>
<p>A similar product that was given subcutaneously, sublingually, or intramuscularly (and not initially metabolized by the liver) is associated with delayed immunoallergic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Caution should be exercised when using ELMIRON<span class="Sup">®</span> in patients who have a history of heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> is associated with pentosan polysulfate and with heparin products. In clinical trials of ELMIRON<span class="Sup">®</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> reported were <span class="product-label-link" type="condition" conceptid="141933" conceptname="Alopecia areata">alopecia areata</span>, limited to a single area on the scalp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a8cfc32-f9e6-49b1-8df9-596946fc4f34"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">ELMIRON<span class="Sup">®</span> has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Because there is evidence of hepatic contribution to the elimination of ELMIRON<span class="Sup">®</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may have an impact on the pharmacokinetics of ELMIRON<span class="Sup">®</span>. Caution should be exercised when using ELMIRON<span class="Sup">®</span> in this patient population.</p>
<p>Mildly (&lt; 2.5 × normal) elevated transaminase, alkaline phosphatase, γ-glutamyl transpeptidase, and lactic dehydrogenase occurred in 1.2% of patients. The increases usually appeared 3 to 12 months after the start of ELMIRON<span class="Sup">®</span> therapy, and were not associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other clinical signs or symptoms. These abnormalities are usually transient, may remain essentially unchanged, or may rarely progress with continued use. Increases in PTT and PT (&lt; 1% for both) or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (0.2%) were noted.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_54d8403c-36a8-47ae-903c-cfa16fae2d17"></a><a name="section-8.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed. Patients should be reminded that ELMIRON<span class="Sup">®</span> has a weak anticoagulant effect. This effect may increase <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_7e0d1688-6615-4aa6-9c89-12f891652592"></a><a name="section-8.4"></a><p></p>
<h2>Laboratory Test Findings</h2>
<p class="First">Pentosan polysulfate sodium did not affect <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) or partial thromboplastin time (PTT) up to 1200 mg per day in 24 healthy male subjects treated for 8 days. Pentosan polysulfate sodium also inhibits the generation of factor Xa in plasma and inhibits thrombin-induced platelet aggregation in human platelet rich plasma <span class="Italics">ex vivo</span>. (See <span class="Bold"><span class="Italics"><a href="#i4i_section_id_9a8cfc32-f9e6-49b1-8df9-596946fc4f34">PRECAUTIONS-<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></span></span> Section for additional information.)</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_13b31ef7-85a1-4024-9c61-5412dd4f3be1"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenicity, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term carcinogenicity studies of ELMIRON<span class="Sup">®</span> in F344/N rats and B6C3F1 mice have been conducted. In these studies, ELMIRON<span class="Sup">®</span> was orally administered once daily via gavage, 5 days per week, for up to 2 years. The dosages administered to mice were 56, 168 or 504 mg/kg. The dosages administered to rats were 14, 42, or 126 mg/kg for males, and 28, 84, or 252 mg/kg for females. The dosages tested were up to 60 times the maximum recommended human dose (MRHD) in rats, and up to 117 times the MRHD in mice, on a mg/kg basis. The results of these studies in rodents showed no clear evidence of drug-related tumorigenesis or carcinogenic risk.</p>
<p>Pentosan polysulfate sodium was not clastogenic or mutagenic when tested in the mouse micronucleus test or the Ames test (<span class="Italics">S. typhimurium</span>). The effect of pentosan polysulfate sodium on spermatogenesis has not been investigated.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b9ad35cb-951a-4afc-8ac8-8289cd6074d6"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy Category B</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_3c5336a4-5dbd-4f84-90e4-19773b6ea737"></a><a name="section-8.6.1"></a><p></p>
<p class="First">Reproduction studies have been performed in mice and rats with intravenous daily doses of 15 mg/kg, and in rabbits with 7.5 mg/kg. These doses are 0.42 and 0.14 times the daily oral human doses of ELMIRON<span class="Sup">®</span> when normalized to body surface area. These studies did not reveal evidence of impaired fertility or harm to the fetus from ELMIRON<span class="Sup">®</span>. Direct <span class="Italics">in vitro</span> bathing of cultured mouse embryos with pentosan polysulfate sodium (PPS) at a concentration of 1 mg/mL may cause reversible limb bud abnormalities. Adequate and well-controlled studies have not been performed in pregnant women. Because animal studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7725bccb-7835-4a3e-b2aa-010c291637f6"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ELMIRON<span class="Sup">®</span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_8d47075e-ae9f-4122-919e-aa2606debd16"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 16 years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_00be3d73-5779-45da-8a80-761918eeae8b"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">ELMIRON<span class="Sup">®</span> was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3–month trial and the remaining 2499 patients were in a long-term, unblinded trial.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months. The <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known.</p>
<p>Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> that required hospitalization. Because there was not a control group of patients with interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> who were concurrently evaluated, it is difficult to determine which events are associated with ELMIRON<span class="Sup">®</span> and which events are associated with concurrent illness, medicine, or other factors.</p>
<a name="_RefID71AE9AF2740842078A1C395425C1CE74"></a><table width="100%">
<caption><span>Adverse Experience in Placebo-Controlled Clinical Trials of ELMIRON<span class="Sup">®</span> 100 mg Three Times a Day for 3 Months </span></caption>
<col width="23%">
<col width="15%">
<col width="10%">
<thead><tr class="First Last Toprule">
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Body System/Adverse Experience</span></th>
<th class="Botrule Lrule" align="center" valign="top">
<span class="Bold">ELMIRON<span class="Sup">®</span></span><br><span class="Bold">n = 128</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">n = 130</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Within a body system, the individual events do not sum to equal overall number of patients because a patient may have more than one event.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td><p class="First"><span class="Bold">CNS</span> Overall Number of Patients<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p></td>
<td><p class="First">3</p></td>
<td class="Lrule Rrule"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">  Severe <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span>/<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td><p class="First">2</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">GI</span> Overall Number of Patients<a href="#footnote-8" class="Sup">*</a></p></td>
<td><p class="First">7</p></td>
<td class="Lrule Rrule"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">3</p></td>
<td class="Lrule Rrule"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">3</p></td>
<td class="Lrule Rrule"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Skin/Allergic</span> Overall Number of Patients<a href="#footnote-8" class="Sup">*</a></p></td>
<td><p class="First">2</p></td>
<td class="Lrule Rrule"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Other</span> Overall Number of Patients<a href="#footnote-8" class="Sup">*</a></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td><p class="First">0</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></p></td>
<td><p class="First">1</p></td>
<td class="Lrule Rrule"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">Total Events</p></td>
<td><p class="First">17</p></td>
<td class="Lrule Rrule"><p class="First">27</p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First">Total Number of Patients Reporting Adverse Events</p></td>
<td><p class="First">13</p></td>
<td class="Lrule Rrule"><p class="First">19</p></td>
</tr>
</tbody>
</table>
<p>The adverse events described below were reported in an unblinded clinical trial of 2499 interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> patients treated with ELMIRON<span class="Sup">®</span>. Of the original 2499 patients, 1192 (48%) received ELMIRON<span class="Sup">®</span> for 3 months; 892 (36%) received ELMIRON for 6 months; and 598 (24%) received ELMIRON<span class="Sup">®</span> for one year, 355 (14%) received ELMIRON<span class="Sup">®</span> for 2 years, and 145 (6%) for 4 years.</p>
<p>Frequency (1 to 4%): <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> (4%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (3%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (2%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2%), liver function abnormalities (1%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1%).</p>
<p>Frequency (≤ 1%):</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcer</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>.</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, increased partial thromboplastin time, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Hypersensitive Reactions:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_502ec74d-ca1a-4842-aa5d-41d5281ffbf4"></a><a name="section-9.1"></a><p></p>
<h2>Post-Marketing Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f50b9e80-6e8f-4de8-a560-0ecb683bafda"></a><a name="section-9.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal Hemorrhage</span></h3>
<p class="First">ELMIRON<span class="Sup">®</span> was evaluated in a randomized, double-blind, parallel group, Phase 4 study conducted in 380 patients with interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> dosed for 32 weeks. At a daily dose of 300 mg (n = 128), <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> was reported as an adverse event in 6.3% of patients. The severity of the events was described as "mild" in most patients. Patients in that study who were administered ELMIRON<span class="Sup">®</span> 900 mg daily, a dose higher than the approved dose, experienced a higher incidence of <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, 15%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_012e9890-ada8-485a-aa09-dc4cb9da2e49"></a><a name="section-9.1.2"></a><p></p>
<h3>Liver Function Abnormality</h3>
<p class="First">A randomized, double-blind, parallel group, phase 2 study was conducted in 100 men (51 ELMIRON<span class="Sup">®</span> and 49 placebo) dosed for 16 weeks. At a daily dose of 900 mg, a dose higher than the approved dose, elevated liver function tests were reported as an adverse event in 11.8% (n = 6) of ELMIRON<span class="Sup">®</span>-treated patients and 2% (n = 1) of placebo-treated patients.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_82607a98-7b2f-4ecd-9bdb-9e4a7555abb8"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> has not been reported. Based upon the pharmacodynamics of the drug, toxicity is likely to be reflected as anticoagulation, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, liver function abnormalities, and gastric distress. (See <span class="Bold"><span class="Italics"><a href="#i4i_clinical_pharmacology_id_28d0b4c7-671d-4581-b941-1deb90551e12">CLINICAL PHARMACOLOGY</a></span></span> and <span class="Bold"><span class="Italics"><a href="#i4i_precautions_id_04abcadb-c70c-4f88-ba54-551ddeee3b6f">PRECAUTIONS</a></span></span> sections.) At a daily dose of 900 mg for 32 weeks (n = 127) in a clinical trial, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> was reported as an adverse event in 15% of patients. At a daily dose of ELMIRON<span class="Sup">®</span> 900 mg for 16 weeks in a clinical trial that enrolled 51 patients in the ELMIRON<span class="Sup">®</span> group and 49 in the placebo group, elevated liver function tests were reported as an adverse event in 11.8% of patients in the ELMIRON<span class="Sup">®</span> group and 2% of patients in the placebo group. In the event of acute overdosage, the patient should be given gastric lavage if possible, carefully observed and given symptomatic and supportive treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_150936c8-1b58-4ce3-b75c-1cd60f897068"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of ELMIRON<span class="Sup">®</span> is 300 mg/day taken as one 100 mg capsule orally three times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals.</p>
<p>Patients receiving ELMIRON<span class="Sup">®</span> should be reassessed after 3 months. If improvement has not occurred and if limiting adverse events are not present, ELMIRON<span class="Sup">®</span> may be continued for another 3 months.</p>
<p>The clinical value and risks of continued treatment in patients whose <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> has not improved by 6 months is not known.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fdd1347a-fd3e-4369-a1bd-c4bd1d8ebf65"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ELMIRON<span class="Sup">®</span> is supplied in white opaque hard gelatin capsules imprinted "BNP7600" containing 100 mg pentosan polysulfate sodium. Supplied in bottles of 100 capsules.</p>
<p>NDC NUMBER 50458-098-01</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_60549fc3-7fdc-457d-adff-2383878440a5"></a><a name="section-12.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at controlled room temperature 15°–30°C (59°–86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4359d013-b5a8-456f-84bd-66db573209b8"></a><a name="section-13"></a><p></p>
<p class="First">ELMIRON<span class="Sup">®</span> is a Registered Trademark of Teva Branded Pharmaceutical Products R&amp;D, Inc. under license to Janssen Pharmaceuticals, Inc.</p>
<p>© Janssen Pharmaceuticals, Inc. 2002,1998</p>
<p>(logo)</p>
<p>Manufactured by:<br>Janssen Ortho LLC<br>Gurabo, Puerto Rico 00778</p>
<p>Product of Germany</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, New Jersey 08560</p>
<p>Revised August 2012</p>
<p><span class="Bold">PHARMACIST: PLEASE DISPENSE ONE PATIENT LEAFLET PER PRESCRIPTION</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_b7bcacd5-7e69-418a-87a5-ab9bac364fd6"></a><a name="section-14"></a><p></p>
<h1>Patient Leaflet</h1>
<p class="First">Questions and Answers About</p>
<p><span class="Bold">ELMIRON<span class="Sup">®</span></span><br><span class="Bold">(Generic name = pentosan polysulfate sodium)</span><br><span class="Bold">Capsules</span></p>
<div class="Warning">
<a name="i4i_table_id_b5118e4b-ab04-4975-8b77-a601fac8110b"></a><a name="section-14.1"></a><p></p>
<h2>What is the most important information I should know about ELMIRON<span class="Sup">®</span>?</h2>
<p class="First">ELMIRON<span class="Sup">®</span> (pronounced EL ma ron) is used to treat the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> (IC).</p>
<p> </p>
<p>You must take ELMIRON<span class="Sup">®</span> as prescribed by your doctor in the dosage prescribed but no more frequently than prescribed.</p>
<p> </p>
<p>ELMIRON<span class="Sup">®</span> is a weak anticoagulant (blood thinner) which may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p> </p>
<p>Call your doctor if you will be undergoing surgery or will begin taking anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin, or anti-inflammatory drugs such as ibuprofen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8517cbc7-160a-42f1-94aa-2eac66b0af11"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">What is ELMIRON<span class="Sup">®</span>?</span></p>
<p>ELMIRON<span class="Sup">®</span> is used to treat the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of interstitial <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> (IC). It is not known exactly how ELMIRON<span class="Sup">®</span> works, but it is not a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication like aspirin or acetaminophen and therefore must be taken continuously for relief as prescribed.</p>
<p><span class="Bold">Who should not take ELMIRON<span class="Sup">®</span>?</span></p>
<dl>
<dt>•</dt>
<dd>Patients undergoing surgery should speak with their doctor about when to discontinue ELMIRON<span class="Sup">®</span> prior to surgery.</dd>
<dt>•</dt>
<dd>ELMIRON<span class="Sup">®</span> should be used during pregnancy only if clearly needed.</dd>
</dl>
<p><span class="Bold">What does your doctor need to know?</span></p>
<dl>
<dt>•</dt>
<dd>If you are taking anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin, or anti-inflammatory drugs such as ibuprofen.</dd>
<dt>•</dt>
<dd>If you are pregnant.</dd>
<dt>•</dt>
<dd>If you have any liver problems.</dd>
</dl>
<p><span class="Bold">How should I take ELMIRON<span class="Sup">®</span>?</span></p>
<p>You should take 1 capsule of ELMIRON<span class="Sup">®</span> by mouth three times a day, with water at least 1 hour before meals or 2 hours after meals. Each capsule contains 100 mg of ELMIRON<span class="Sup">®</span>.</p>
<p><span class="Bold">What should I avoid while taking ELMIRON<span class="Sup">®</span>?</span></p>
<p>Anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin or anti-inflammatory drugs such as ibuprofen until you speak with your doctor.</p>
<p><span class="Bold">What are the most common side effects of ELMIRON<span class="Sup">®</span>?</span></p>
<p>The most common side effects are <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, blood in the stool, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</p>
<p>Call your doctor if these side effects persist or are bothersome or if there is blood in your stool.</p>
<p>If you suspect that someone may have taken more than the prescribed dose of this medicine, contact your local poison control center or emergency room immediately. This medication was prescribed for your particular condition. Do not use it for another condition or give the drug to others.</p>
<p>This leaflet provides a summary of information about ELMIRON<span class="Sup">®</span>. Medicines are sometimes prescribed for uses other than those listed in a Patient Leaflet. If you have any questions or concerns, or want more information about ELMIRON<span class="Sup">®</span>, contact your doctor or pharmacist. Your pharmacist also has a longer leaflet about ELMIRON<span class="Sup">®</span> that is written for health professionals that you can ask to read.</p>
<p>ELMIRON<span class="Sup">®</span> is a Registered Trademark of Teva Branded Pharmaceutical Products R&amp;D, Inc. under license to Janssen Pharmaceuticals, Inc.</p>
<p>© Janssen Pharmaceuticals, Inc. 2002,1998</p>
<p>(logo)</p>
<p>Janssen Pharmaceuticals, Inc.<br>Titusville, New Jersey 08560</p>
<p>Revised August 2012</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c9eae8b2-e1e9-408e-942c-0535d33815e5"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">NDC 55154-0553-8</p>
<p>Contains Approximately 3300 Capsules</p>
<p>ELMIRON<span class="Sup">®</span></p>
<p>(pentosan polysulfate sodium) capsules</p>
<p>100 mg</p>
<p>Each capsule contains 100 mg pentosan polysulfate sodium.</p>
<p>Rx ONLY</p>
<p>WARNING: Keep out of reach of children.</p>
<div class="Figure">
<a name="id1872652607"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b172ad2-074f-4534-af1f-89d951647ee9&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5deaea03-946a-4a2c-ab56-3a1818d15209"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">NDC 55154-0553-2</p>
<p>Contains Approximately 1600 Capsules</p>
<p>ELMIRON<span class="Sup">®</span></p>
<p>(pentosan polysulfate sodium) capsules</p>
<p>100 mg</p>
<p>Each capsule contains 100 mg pentosan polysulfate sodium.</p>
<p>Rx ONLY</p>
<p>WARNING: Keep out of reach of children.</p>
<div class="Figure">
<a name="id769"></a><img alt="Elmiron Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b172ad2-074f-4534-af1f-89d951647ee9&amp;name=image-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELMIRON 		
					</strong><br><span class="contentTableReg">pentosan polysulfate sodium capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-0553(NDC:50458-098)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENTOSAN POLYSULFATE SODIUM</strong> (PENTOSAN POLYSULFATE) </td>
<td class="formItem">PENTOSAN POLYSULFATE SODIUM</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE OPAQUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BNP7600</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-0553-8</td>
<td class="formItem">3300  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-0553-2</td>
<td class="formItem">1600  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020193</td>
<td class="formItem">09/26/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-0553)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4a7e3723-9842-45b6-b24e-e3c800247f71</div>
<div>Set id: 3b172ad2-074f-4534-af1f-89d951647ee9</div>
<div>Version: 4</div>
<div>Effective Time: 20140701</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
